Comment on Laber et al [0.03%]
对Laber等人的评论
M Elizabeth Halloran,Michael G Hudgens
M Elizabeth Halloran
AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials [0.03%]
AAA：在双剂剂量寻找试验中识别最佳剂量组合的三重自适应贝叶斯设计方法
Jiaying Lyu,Yuan Ji,Naiqing Zhao et al.
Jiaying Lyu et al.
We propose a flexible design for the identification of optimal dose combinations in dual-agent dose finding clinical trials. The design is called AAA, standing for three adaptations: adaptive model selection, adaptive dose insertion and ada...
Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times [0.03%]
基于多事件时间的异种癌症患者自然杀伤细胞剂量优化方法研究
Juhee Lee,Peter F Thall,Katy Rezvani
Juhee Lee
A sequentially adaptive Bayesian design is presented for a clinical trial of cord blood derived natural killer cells to treat severe hematologic malignancies. Given six prognostic subgroups defined by disease type and severity, the goal is ...
Informing a Risk Prediction Model for Binary Outcomes with External Coefficient Information [0.03%]
基于外部信息的二分类风险预测模型变量选择及估计方法研究
Wenting Cheng,Jeremy M G Taylor,Tian Gu et al.
Wenting Cheng et al.
We consider a situation where there is rich historical data available for the coefficients and their standard errors in an established regression model describing the association between a binary outcome variable Y and a set of predicting f...
Correlated multistate models for multiple processes: an application to renal disease progression in systemic lupus erythematosus [0.03%]
用于系统性红斑狼疮肾病进展的多重过程的相关多状态模型：一项应用研究
Aidan G O&#x;Keeffe,Li Su,Vernon T Farewell
Aidan G O&#x;Keeffe
Bidirectional changes over time in the estimated glomerular filtration rate and in urine protein content are of interest for the treatment and management of patients with lupus nephritis. Although these processes may be modelled by separate...
An information theoretic phase I-II design for molecularly targeted agents that does not require an assumption of monotonicity [0.03%]
一种不需要单调性假设的分子靶向药物信息论一期和二期设计
Pavel Mozgunov,Thomas Jaki
Pavel Mozgunov
For many years phase I and phase II clinical trials have been conducted separately, but there has been a recent shift to combine these phases. Although a variety of phase I-II model-based designs for cytotoxic agents have been proposed in t...
Mediation analysis for count and zero-inflated count data without sequential ignorability and its application in dental studies [0.03%]
牙科研究中的计数和零膨胀计数数据的介导分析及其应用
Zijian Guo,Dylan S Small,Stuart A Gansky et al.
Zijian Guo et al.
Mediation analysis seeks to understand the mechanism by which a treatment affects an outcome. Count or zero-inflated count outcomes are common in many studies in which mediation analysis is of interest. For example, in dental studies, outco...
Bayesian log-Gaussian Cox process regression: with applications to meta-analysis of neuroimaging working memory studies [0.03%]
基于贝叶斯log-高斯Cox过程的回归及其在神经影像学工作记忆研究中的应用META分析
Pantelis Samartsidis,Claudia R Eickhoff,Simon B Eickhoff et al.
Pantelis Samartsidis et al.
Working memory (WM) was one of the first cognitive processes studied with functional magnetic resonance imaging (fMRI). With now over 20 years of studies on WM, each study with tiny sample sizes, there is a need for meta-analysis to identif...
A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data [0.03%]
基于时间毒性数据的联合治疗一期临床试验的无模型贝叶斯方法
Graham M Wheeler,Michael J Sweeting,Adrian P Mander
Graham M Wheeler
The product of independent beta probabilities escalation (PIPE) design for dual-agent phase I dose-escalation trials is a Bayesian model-free approach for identifying multiple maximum tolerated dose combinations of novel combination therapi...
Two-stage design for phase I-II cancer clinical trials using continuous dose combinations of cytotoxic agents [0.03%]
细胞毒药物连续剂量组合I-II期抗癌临床试验的两阶段设计
Mourad Tighiouart
Mourad Tighiouart
We present a two-stage phase I/II design of a combination of two drugs in cancer clinical trials. The goal is to estimate safe dose combination regions with a desired level of efficacy. In stage I, conditional escalation with overdose contr...